C3L-02616
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 63.72347707
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.420
- PANCREAS_BETA_CELLS+0.360
- SPERMATOGENESIS+0.310
- MITOTIC_SPINDLE+0.140
- KRAS_SIGNALING_DN+0.050
- MYC_TARGETS_V2+0.030
- MYC_TARGETS_V1+0.000
- HEDGEHOG_SIGNALING-0.010
- MYOGENESIS-0.010
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.550
- INTERFERON_ALPHA_RESPONSE-0.550
- TNFA_SIGNALING_VIA_NFKB-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- ANGIOGENESIS-0.460
- GLYCOLYSIS-0.460
- ANDROGEN_RESPONSE-0.450
- APOPTOSIS-0.440
- INTERFERON_GAMMA_RESPONSE-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HHPA8NJ2 | medulloblastoma | — | 0.944 |
| 2 | BS_VVFBW0YH | medulloblastoma | — | 0.944 |
| 3 | BS_1TWCV047 | Embryonal tumors | — | 0.941 |
| 4 | BS_NZ71XCG3 | medulloblastoma | — | 0.939 |
| 5 | BS_W311713R | medulloblastoma | — | 0.935 |
| 6 | BS_QRDT19KS | medulloblastoma | — | 0.926 |
| 7 | BS_W9AT0MR7 | medulloblastoma | — | 0.924 |
| 8 | BS_QEYPFYHD | medulloblastoma | — | 0.920 |
| 9 | BS_4W68NV3M | medulloblastoma | — | 0.916 |
| 10 | SRR934905 | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.030 | Idelalisib | — uncovered |